Muaz Ali

Muaz Ali

Auto-generated profile, based on publicly available information

Muaz Ali

Department of Neurology, Cleveland Clinic Florida

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2026 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
MAMuaz Ali
Muaz Ali
ASArkansh Sharma
Arkansh Sharma
APAmith Paruchuri
Amith Paruchuri
FSFaizan Shahzad
Faizan Shahzad
MKMarwah Bintay Khalid
Marwah Bintay Khalid
Vinay SureshVinay Suresh
Vinay Suresh
Background: Current therapies for Parkinson’s disease lack proven disease-modifying effects. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for type 2 diabetes, have shown potential neuroprotective properties. Their comparative efficacy in Parkinson’s disease remains unclear. Methods: A systematic search (inception–February 2026) identified randomized controlled trials evaluating GLP-1RAs in Parkinson’s disease. Pairwise and frequentist random-effects network meta-analyses were performed. The primary outcome was MDS-UPDRS Part III (ON state). Results: Five trials ( n = 708) were included. Pairwise meta-analysis showed no significant overall improvement in MDS-UPDRS Part III (MD –2.00; 95% CI –5.46 to 1.46; I² = 80.5%). Network meta-analysis demonstrated significant ON-state motor improvement with Exenatide 20 µg/day (MD –9.80; 95% CI –14.47 to –5.13) and Lixisenatide 20 µg/day (MD –3.08; 95% CI –5.31 to –0.85). No significant effects were observed for MDS-UPDRS Part III (OFF-state) or other domains (Parts I, II, and IV; ON-state). NLY01 at 5 mg/week improved PDQ-39, while NMSS showed dose-dependent divergence. Gastrointestinal adverse events were more frequent with GLP-1RAs. Conclusion: GLP-1 receptor agonists may provide dose-specific motor benefits in Parkinson’s disease, but evidence for broader clinical improvement is limited. Larger, longer-duration trials are needed.

26 November 2025 in Exploratory Research and Hypothesis in Medicine
Verified
Journal Article
Open access
MAMuaz Ali
Muaz Ali
AMAbdaal Munir
Abdaal Munir
JMJamal Montaser
Jamal Montaser
STSrihas Tumu
Srihas Tumu
VRVenkata Yashashwini Maram Reddy
Venkata Yashashwini Maram Reddy
IMIana Malasevskaia
Iana Malasevskaia
Temporal lobe epilepsy (TLE) is the most common focal epilepsy, with many patients developing drug-resistant epilepsy. Surgical interventions, including stereoelectroencephalography (SEEG)-guided temporal lobe resection (TLR) and SEEG-guided responsive neurostimulation (RNS), are key treatment options. This systematic review compares the efficacy and safety of these interventions in drug-resistant TLE.

17 February 2026 in Anz Journal of Surgery
Verified
Journal Article
Closed access
AMAbdaal Munir
Abdaal Munir
JMJamal Montaser
Jamal Montaser
STSrihas Tumu
Srihas Tumu
VRVenkata Yashashwini Maram Reddy
Venkata Yashashwini Maram Reddy
NJNavod Jayasuriya
Navod Jayasuriya
IMIana Malasevskaia
Iana Malasevskaia

1 September 2026 in Neurology Open Access
Verified
Journal Article
Closed access
MAMuaz Ali
Muaz Ali
LHLiang Hong
Liang Hong
ANAmre Nouh
Amre Nouh

1 July 2026 in Stroke
Verified
Journal Article
Closed access
ANAmre Nouh
Amre Nouh
DODaiWai M. Olson
DaiWai M. Olson
HLHong Liang
Hong Liang
AKAhmed Koriesh
Ahmed Koriesh
MAMuaz Ali
Muaz Ali
GFGregg C. Fonarow
Gregg C. Fonarow
BACKGROUND: In-hospital stroke is associated with delayed recognition and worse outcomes compared with community-onset stroke. Contemporary national data in the mechanical thrombectomy (MT) era are limited. METHODS: We performed a retrospective cohort study of adult ischemic stroke admissions in the Get With The Guidelines-Stroke registry from January 2016 to December 2023 (the MT era). In-hospital stroke was compared with community-onset stroke as the primary analysis. A secondary descriptive analysis comparing in-hospital patients with stroke from January 2006 to April 2012 and January 2016 to December 2023 was also performed. Primary outcomes were in-hospital mortality, discharge home, and independent ambulation at discharge. Multivariable logistic regression with generalized estimating equations accounted for within-hospital clustering and adjusted for demographics, vascular risk factors/comorbidities, and hospital characteristics. Temporal trends in MT use were assessed with the Cochran-Armitage trend test. RESULTS: Among 4 996 392 ischemic stroke admissions from 2016 to 2023, 191 355 (3.8%) were in-hospital, and 4 805 037 (96.2%) were community onset. In-hospital patients presented with greater severity (National Institutes of Health Stroke Scale score >20: 14.5% versus 7.9%; National Institutes of Health Stroke Scale score, 0–4: 43.3% versus 60.4%) had worse outcomes including higher in-hospital mortality (adjusted odds ratio, 2.27 [95% CI, 2.18–2.36]; P <0.001), lower likelihood of discharge home (adjusted odds ratio, 0.46 [95% CI, 0.45–0.48]; P <0.001), and lower independent ambulation at discharge (adjusted odds ratio, 0.52 [95% CI, 0.50–0.53]; P <0.001). Recognition-to-computed tomography time was longer for in-hospital (median 51 [interquartile range, 16–269] versus 18 [10–39] minutes; P <0.001). MT rates increased significantly from 2016 to 2023 in both in-hospital and community-onset patients (4.47%–9.54% and 2.35%–5.55%, respectively; P <0.001). Quality metrics and outcomes significantly improved in the MT era, independent of treatment modality. CONCLUSIONS: In patients with in-hospital stroke, MT rates increased over time, and improvements in quality metrics were observed regardless of treatment modality. A higher level of stroke severity and worse outcomes persists.

28 September 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
MAMuaz Ali
Muaz Ali
HSHaroon Shabbir
Haroon Shabbir
MSMaheen Shaharyar
Maheen Shaharyar
SMSindu Mukesh
Sindu Mukesh
ARAdriana Rodriguez
Adriana Rodriguez
AKAhmed Koriesh
Ahmed Koriesh
Background: Anti-amyloid monoclonal antibodies offer a treatment strategy for early Alzheimer's disease, but their modest efficacy must be weighed against important safety concerns. Objective: To evaluate the efficacy and safety of aducanumab, lecanemab, and donanemab in randomized placebo-controlled trials. Methods: PubMed, Cochrane, and ClinicalTrials.gov were searched through February 2026 for randomized placebo-controlled trials evaluating aducanumab, lecanemab, or donanemab in early symptomatic Alzheimer's disease. Outcomes included Clinical Dementia Rating–Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), amyloid-related imaging abnormalities–edema/effusion (ARIA-E), amyloid-related imaging abnormalities–hemosiderin deposition (ARIA-H), and APOE ε4-stratified ARIA-E. Random-effects meta-analyses were performed. Results: Seven trials were included. Treatment favored intervention for ADAS-Cog (SMD −0.15, 95% CI −0.21 to −0.10), CDR-SB (MD −0.41, 95% CI −0.63 to −0.18), and MMSE (MD 0.44, 95% CI 0.03 to 0.86), although effects were small. Treatment increased ARIA-E (23.9% versus 1.9%; RR 11.65, 95% CI 9.06 to 14.99) and ARIA-H (16.8% versus 6.8%; RR 2.45, 95% CI 1.94 to 3.09). Among treated participants with APOE ε4-stratified ARIA-E data, APOE ε4 carriers had higher ARIA-E risk than non-carriers (29.3% versus 13.8%; RR 2.10, 95% CI 1.67 to 2.64). Brain-volume loss, ventricular enlargement, and treatment-related deaths were narratively identified but not pooled. Conclusions: Aducanumab, lecanemab, and donanemab showed statistically significant but small slowing of decline that may not reach patient-perceptible clinical meaningfulness. Increased ARIA risk and additional safety signals support cautious selection, imaging surveillance, and individualized risk-benefit discussions.